For molecular response, changed "QPCR" to "QPCR using the International Scale"

For major molecular response, changed criteria to "at least a 3-log reduction in BCR-ABL levels, or BCR-ABL 0.1%, found by QPCR using the International Scale"

Added relapse criteria to chart

Part 5.3.2 – Recommended follow-up testing schedule for TKI therapy

Page 50

Completely changed format of chart and test details and recommendations included in chart

For bone marrow cytogenetics, added that it is recommended "at any scheduled follow-up after starting treatment if QPCR using the International Scale is not available to assess treatment response"

Changed "QPCR" to "QPCR using the International Scale"

Part 5.3 – Follow-up tests and treatment responses

Page 53

Added chart explaining the International Scale for QPCR

Part 5.4.1 – Chronic phase 3-month follow-up treatment

Page 55

Under "Test results" – changed response criteria to "BCR-ABL ≤ 10% by QPCR using the International Scale or Partial cytogenetic response on bone marrow cytogenetics" and "BCR-ABL > 10% by QPCR using the International Scale or Less than a partial cytogenetic response on bone marrow cytogenetics"

In top half of chart, added follow-up recommendations for "No relapse" and "Relapse"

In bottom half of chart for prior imatinib treatment, added option "Increase imatinib dose up to 800 mg as tolerated, if not candidate for other TKI"

In bottom half of chart for prior nilotinib or dasatinib treatment, added option "Continue same dose of nilotinib or dasatinib"

Part 5.4.2 – Chronic phase 6-month follow-up treatment

Page 58

Under "Test results" – changed response criteria to "BCR-ABL ≤ 10% by QPCR using the International Scale or At least a partial cytogenetic response on bone marrow cytogenetics" and "BCR-ABL > 10% by QPCR using the International Scale or Less than a partial cytogenetic response on bone marrow cytogenetics"

Under "Follow-up treatment" – changed options based on changes to test results criteria

Added note below chart stating: "These 6-month follow-up recommendations are only for patients who, at the 3-month follow-up, had BCR-ABL >10% or had less than a partial cytogenetic response."